This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
Why Is Merck (MRK) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bayer's Aliqopa Gets Breakthrough Therapy Status by FDA
by Zacks Equity Research
Bayer's (BAYRY) Aliqopa gets Breakthrough Thearpy designation from the FDA for the treatment of adult patients with relapsed marginal zone lymphoma, who have received at least two prior therapies.
Merck (MRK) Up This Year So Far: Will the Momentum Continue?
by Kinjel Shah
Merck's shares are up 6.2% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
J&J Stock Up This Year So Far: Will the Momentum Continue?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Dow on Longest Losing Streak in 8 Yrs: 5 Stocks Still Up in ETF
by Sweta Killa
The Dow Jones fell for a fifth straight week - representing the longest losing streak since June 2011 on intensifying trade dispute. Though most of the stocks in the fund's portfolio pushed the dow ETF down, a few are still in green.
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
Glaxo's Shingles Vaccine Shingrix Gets Approval in China
by Zacks Equity Research
GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
by Zacks Equity Research
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
by Swarup Gupta
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
Synlogic (SYBX) Enters Cancer Collaboration with Roche
by Zacks Equity Research
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
J&J's Invokana sNDA Gets Priority Review Status From FDA
by Zacks Equity Research
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
Array BioPharma Gains on Colorectal Cancer Study Success
by Zacks Equity Research
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Company News For May 22, 2019
by Zacks Equity Research
Companies In The News Are: KSS,AZO,HD,MRK
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Merck's Keytruda Fails in Late-Stage Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AbbVie's Brain Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
by Kinjel Shah
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
by Zacks Equity Research
FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
4 Dow Stocks to Buy on the Dip Despite Market Volatility
by Nalak Das
After an impressive bull run in the first four months of this year, it seems volatility is once again ready to rear its ugly face in Wall Street.
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer
by Zacks Equity Research
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.